CDK4 and glioblastoma: Currently, abemaciclib and ribociclib, two kinds of CDK4/6 inhibitors, are being explored in phase I trials for pediatric and adult patients with glioblastoma, although palbociclib, a dual CDK4/6 inhibitor, is ineffective in the treatment of recurrent glioblastoma [11–13].